IMMURON Total Assets 2018-2024 | IMRN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON total assets from 2018 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON total assets from 2018 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$220.6B
Amgen (AMGN)	$158.8B
Gilead Sciences (GILD)	$136.4B
Vertex Pharmaceuticals (VRTX)	$120.4B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$78.4B
CSL (CSLLY)	$76.6B
Regeneron Pharmaceuticals (REGN)	$61.3B
Alnylam Pharmaceuticals (ALNY)	$41.1B
Argenex SE (ARGX)	$34.2B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$19.7B
Insmed (INSM)	$18.6B
Illumina (ILMN)	$15.7B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.7B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$13B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.4B
Roivant Sciences (ROIV)	$7.7B
Repligen (RGEN)	$7.3B